Pathogenesis and Management of Acquired Haemophilia

References

• Garvey, M. B. (1995). Incidence and management of patients with acquired factor VIII inhibitors: the practical experience of a tertiary care hospital. In: “Acquired Halmophilia”, Edited by Kessler, C., pp. 91–111. Princeton, Exerpta Medica Inc.
   Google Scholar
• Evans, E. N. and Majer, R. V. (1995). Acquired Haemophilia: an important but often unrecognised cause of bleeding in elderly people, (letter), BMJ, 311, 679.
   PubMed Web of Science ®Google Scholar
• Green, D., Rademaker, A. W. and Briët, E. (1993). A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb. Haemost., 70, 753–757.
   PubMed Web of Science ®Google Scholar
• Green, D. and Lechner, K. (1981). A survey of 215 non-haemophilic patients with inhibitors to factor VIII. Thromb. Haemost., 45, 200–203.
   PubMed Web of Science ®Google Scholar
• Morrison, A. E., Ludlam, C. A. and Kessler, C. (1993). Use of porcine factor VIII in the treatment of patients with acquired haemophilia. Blood, 6, 1513–1520.
   Google Scholar
• Spero, J. A., Lewis, J. H. and Hasiba, U. (1981). Corticosteroid therapy for acquired FVIII: C inhibitors. Br. J. Haematol., 48, 635–642.
   PubMed Web of Science ®Google Scholar
• Hauser, I., Schneider, B. and Lechner, K. (1995). Postpartum factor VIII inhibitors. A. review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb. Haemost., 73, 1–5.
   PubMed Web of Science ®Google Scholar
• Shaffer, L. G. and Phillips, M. D. (1997). Successful treatment of acquired haemophilia with oral immunosuppressive therapy. Ann. Intern. Med., 127, 206–209.
   PubMed Web of Science ®Google Scholar
• Hay, C. R. M., Negrier, C. and Ludlam, C. A. (1997). The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb. Haemost., 78, 1463–1467.
   PubMed Web of Science ®Google Scholar
• Lottenberg, R., Kentro, T. B. and Kitchens, C. S. (1987). Acquired haemophilia—a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch. Intern. Med., 147, 1077–1081.
   PubMed Web of Science ®Google Scholar
• Hay, C.R.M., Lozier, J.N., Lee, C. A. et al. (1994). Porcine factor VIII therapy in patients with congenital haemophilia and inhibitors: efficacy, patient selection and side effects. Semin. Haematol., 31 (2, suppl. 4), 20–25.
   PubMed Web of Science ®Google Scholar
• Hay, C.R M., Ludlam, C. A., Colvin, B. T. et al. (1998). Factor VIII inhibitors in mild and moderate-severity haemophilia A. Throm. Haemost. 79, 762–766.
   PubMed Web of Science ®Google Scholar
• Ludlam, C. A. (1997). Presentation: anti-factor VIII antibodies arising in mild/moderate haemophilia A. Haemophilia, 3 (suppl 3), 8–9.
   Google Scholar
• Brettler, D. B. (1996). Inhibitors in congenital haemophilia. Baillière's Clin. Haematol., 9(2), 319–329.
   PubMedGoogle Scholar
• Schwartz, R. S., Gabriel, D. A., Aledort, L. M., Green, D. and Kessler, C. M. (1995). A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-close intravenous gammaglobulin. Blood, 86, 797–804.
   PubMed Web of Science ®Google Scholar
• Frick, P. G. (1953). Haemophilia-like disease following pregnancy with transplacental transfer of an acquired circulating anticoagulant. Blood, 8, 598–608.
   PubMed Web of Science ®Google Scholar
• Broxson, E. H. and Hathaway, W. E. (1987). Transplacental transfer of acquired factor VIII: C inhibitor (letter). Thromb. Haemost., 57, 126.
   PubMed Web of Science ®Google Scholar
• Bauer, P., Audibert, G., Bollaert, P. E., Briquel, M. E., Lambert, H. and Larcan, A. (1990). Déficit acquis en facteur VIII coagulant du post-partum avec passage transplacentaire (letter). Presse Médicale, 19, 1547.
   PubMedGoogle Scholar
• Ries, M., Wolfel, D. and Meier-Brandt, B. (1995). Severe intra-cranial haemorrhage in a new-born infant with transplacental transfer of an acquired factor VIII: C inhibitor. J. Pediatrics., 127, 649–650.
   PubMed Web of Science ®Google Scholar
• Labbe, A., Dubray, C., Bezou, M. J., Travade, P. and Coulet, M. (1983). Spontaneously acquired factor VIII inhibitor in a non-haemophiliac child. Acta Paediatrica Scandinavica, 72, 621–623.
   PubMed Web of Science ®Google Scholar
• Geurs, F., Baele, G. and Afschrift, M. (1995). Acquired haemophilia in the elderly. Acta Clinica Belgica, 50, 238–241.
   PubMed Web of Science ®Google Scholar
• Michiels, J. J., Hamulyak, K., Nieuwenhuis, H. K., Novakova, I. and van Vliet, H. H. (1997). Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur. J. Haematol., 59, 105–109.
   PubMed Web of Science ®Google Scholar
• Kadir, R. A., Koh, M. B., Lee, C. A. and Pasi, K. J. (1997). Acquired haemophilia, an unusual cause of severe postpartum haemorrhage. Br. J. Obstet. Gynaecol., 104, 854–856.
   PubMedGoogle Scholar
• Vignes, S., Le Moing, V., Meekel, P., Papo, T., Wechsler, B. and Godeau, P. (1996). Acquired haemophilia: a rare complication of Sjögren's syndrome. Clin. Exp. Rheumatol., 14, 559–560.
   PubMed Web of Science ®Google Scholar
• Sievert, R., Goldstein, M. L. and Surks, M. I. (1996). Graves' disease and autoimmune factor VIII deficiency. Thyroid, 6, 245–247.
   PubMed Web of Science ®Google Scholar
• Shapiro, S. S. and Hultin, M. (1975). Acquired inhibitors to the blood coagulation factors. Seminars in Thrombosis and Haemostasis, 1, 336–385.
   Google Scholar
• Hultin, M. B. (1991). Acquired inhibitors in malignant and nonmalignant disease states. Am. J. Med., 91(5A). 9S–13S.
   PubMedGoogle Scholar
• Ceballo, S. P., Yeche, S., Reynaud, D., Mouliade, C. and Dubois, A. (1996). Inhibiteur acquis du facteur VIII et leucémie lymphoïde chroinque. Á propos d'un cas. Rev. M.éd. Interne., 17, 150–153.
   PubMedGoogle Scholar
• Sherman, L. A., Goldstein, M. D. and Sise, H. S. (1969). Circulating anticoagulant (antifactor VIII) treated with immunosuppressive drugs. Thromb. Diath. Haemorrh., 21, 249–259.
   PubMedGoogle Scholar
• Sise, H. S., Gauthier, J., Desforges, J. and Becker, R. (1962). Spontaneous circulating anticoagulant (antifactor VIII). Am. J. Med., 32, 964–975.
   PubMed Web of Science ®Google Scholar
• Stricker, R. B., Barlogie, B. and Kiprov, D. B. (1994). Acquired Factor VIII inhibitor associated with chronic interferon-α therapy. J. Rheumatol., 21, 350–352.
   PubMed Web of Science ®Google Scholar
• Rizza, C. R., Edgcumbe, J. O. P., Pitney, W. R. and Child, J. A. (1972). The treatment of patients having spontaneously occurring antibodies against antihaemophilic factor (factor VIII). Throm. Diath. Haemorrh., 28, 120–128.
   PubMedGoogle Scholar
• Manson, L. M., Stewart, A. J., Dasani, H., Collins, P. and Ludlam, C. A. (1998). Acquired haemophilia and depot thioxanthene preparations (abstract). Haemophilia, 4, 252.
   Google Scholar
• Seidler, S. W., Mills, L. E., Flowers, M. E. D. and Sullivan, K. M. (1994). Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. Am. J. Haematol., 45, 240–243.
   PubMed Web of Science ®Google Scholar
• Hoyle, C. and Ludlam, C. A. (1986). Acquired factor VIII inhibitor associated with multiple sclerosis, successfully treated with porcine factor VIII (letter). Thromb. Haemost., 57, 233.
   Web of Science ®Google Scholar
• Aurousseau, M. H., Eclache, V., Fain, O. and Thomas, M. (1996). Acquired factor VIII inhibitor in a patient with tuberculosis (letter). Haemostasis, 26, 319–320.
   PubMedGoogle Scholar
• Lin, C. K., Liang, R., Liu, H. W., Tse, P. W. and Chan, G. T. (1991). Myelodysplastic syndrome and acquired factor VIII inhibitor with severe subcutaneous haemorrhage. Acta Haematol., 85, 206–208.
   PubMed Web of Science ®Google Scholar
• Meek, J. C. and Haak, H. L. (1986). Acute myelomonocytic leukaemia and acquired haemophilia A with severe cutaneous haemorrhage. Scandinavian Journal of Haematology, 37, 168–173.
   PubMedGoogle Scholar
• Annichino-Bizzacchi, J. M. and Machado, T. F. (1991). Leprosy and acquired factor VIII inhibitor: a case report. Lepr. Rev., 62, 155–157.
   PubMed Web of Science ®Google Scholar
• Gilles, J. G. G. and Saint-Remy, J. M. R. (1994). Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J. Clin. Invest., 94, 1496–1505.
   PubMed Web of Science ®Google Scholar
• Rossi, F., Sultan, Y. and Kazatchkine, M. D. (1988). Anti-idiotypes against autoantibodies and alloantibodies to factor VIII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin. Exp. Immunol., 74, 311–316.
   PubMed Web of Science ®Google Scholar
• Jacquemin, M. G. and Saint-Remy, J. M. R. (1998). Factor VIII immunogenicity. Haemophilia, 4, 552–557.
   PubMed Web of Science ®Google Scholar
• Cerottini, J. C. and MacDonald, H. R. (1989). The cellular basis of T cell memory. Annu. Rev. Immunol., 7, 77–89.
   PubMed Web of Science ®Google Scholar
• Adelstein, S., Pritchard-Briscoe, H., Anderson, T. A. et al. (1991). Induction of self-tolerance in T cells but not B cells of transgenic mice expressing a little self antigen. Science, 251, 1223–1225.
   PubMed Web of Science ®Google Scholar
• Cook, M. C., Basten, A. and Fazekas de St. Groth, B. (1997). Outer periarteriolar lymphoid sheath arrest and subsequent differentiation of both naive and tolerant immunoglobulin transgenic B cells is determined by B cell receptor occupancy. J. Exp. Med., 186, 631–643.
   PubMed Web of Science ®Google Scholar
• Sultan, Y., Kazatchkine, M. D., Maisonneuve, P. and Nydegger, U. E. (1984). Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high dose intravenous gammaglobulin. Lancet, ii, 765–768.
   Google Scholar
• Gilles, J. G. and Saint-Remy, J. M. R. (1996). Coagulation factor VIII autoantibodies. In: “Autoantibodies”, Edited by Peter, J. B. and Schoenfeld, Y., pp. 172–178. Elsevier.
   Google Scholar
• Ortel, T. L., Quinn-Allen, M. A., Charles, L. A., Devore-Carter, D. and Kane, W. H. (1992). Characterization of an acquired inhibitor to coagulation factor V. Antibody. binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralises procoagulant activity. J. Clin. Invest., 90, 2340–2347.
   PubMed Web of Science ®Google Scholar
• Fulcher, C. A., de Graaf-Mahoney, S. and Zimmerman, T. S. (1987). Factor VIII inhibitor IgG subclass and factor VIII polypeptide specificity determined by immunoblotting. Blood, 69, 1475–1480.
   PubMed Web of Science ®Google Scholar
• Scandella, D., Mattingly, M., De Graaf, S. and Fulcher, C. A. (1989). Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood, 74, 1618–1626.
   PubMed Web of Science ®Google Scholar
• Gawryl, M. S. and Hoyer, L. W. (1982). Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood, 60, 1103–1109.
   PubMed Web of Science ®Google Scholar
• Jacquemin, M. G., Desqueper, B. G., Benhida, A. et al. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a haemophilia A patient with inhibitor. Blood, manuscript in press.
   Google Scholar
• Mudad, R. and Kane, W. H. (1993). DDAVP in acquired haemophilia A: case report and review of the literature. Am. J. Haematol., 43, 295–299.
   PubMed Web of Science ®Google Scholar
• Rizza, C. R. and Biggs, R. (1973). The treatment of patients who have factor VIII antibodies. Br. J. Haematol, 24, 65–82.
   PubMed Web of Science ®Google Scholar
• Cohen, A. J. and Kessler, C. M. (1996). Acquired inhibitors. Baillire's Clin. Haematol., 9(2), 331–354.
   PubMedGoogle Scholar
• Kasper, C. K. (1989). The therapy of factor VIII inhibitors. Progress in Haemostasis and Thrombosis, 9, 57–86.
   PubMedGoogle Scholar
• Blatt, P. M., White II, G. C., Mcmillan, C. W. and Roberts, H. R. (1977). Treatment of anti-factor VIII antibodies. Thromb. Haemost., 38, 514–523.
   PubMed Web of Science ®Google Scholar
• Rizza, C. R. and Matthews, J. M. (1982). Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br. J. Haematol, 52, 13–24.
   PubMed Web of Science ®Google Scholar
• Kessler, C. M. (1994). Factor VIII inhibitors—an algorithmic approach to treatment. Semin. Haematol., 31 (2 suppl. 4), 33–36.
   PubMed Web of Science ®Google Scholar
• Gringeri, A., Santagostino, E., Tradati, F., Giangrande, P. L. F. and Mannucci, P. M. (1991). Adverse effects of treatment with porcine factor VIII. Thromb. Haemost., 65, 245–247.
   PubMed Web of Science ®Google Scholar
• Lusher, J. M. (1998). Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagul. Fibrinolysis., 9 (suppl. 1), S111–S114.
   PubMedGoogle Scholar
• Hedner, U., Glazer, S. and Falch, J. (1993). Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Medicine Reviews, 7(2), 78–83.
   PubMedGoogle Scholar
• Hedner, U. (1996). Dosing and monitoring Novoseven treatment. Blood Coagul. Fibrinolysis., 9 (suppl. 1), S115–S118.
   Google Scholar
• Roberts, H. R. (1998). Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul. Fibrinolysis., 9 (suppl. 1), S115–S118.
   PubMedGoogle Scholar
• Lusher, J. M., Blatt, P. M., Penner, J. A. et al. (1983). Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute haemarthroses in haemophiliacs with inhibitors to factor VIII. Blood, 62, 1135–1138.
   PubMed Web of Science ®Google Scholar
• Lusher, J. M., Shapiro, S. S., Palascak, J. E., Rao, A. V., Levine, P. H. and Blatt, P. M. (1980). Efficacy of prothrombin-complex concentrates in haemophiliacs with antibodies to factor VIII. New Engl. J. Med., 303, 421–425.
   PubMed Web of Science ®Google Scholar
• Sjamsoedin, L. J. M., Heijnen, L., Mauser-Bunschoten, E. P. et al. (1981). The effect of activated prothrombincomplex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. New Engl. J. Med., 305, 717–721.
   PubMed Web of Science ®Google Scholar
• Lusher, J. M. (1993). Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Haematol, 30 (2 suppl. 1), 36–40.
   PubMed Web of Science ®Google Scholar
• Chavin, S. I., Siegel, D. M., Rocco, T. A. and Olson, J. P. (1988). Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am. J. Med., 85, 245–249.
   PubMed Web of Science ®Google Scholar
• Pathare, A. V. and Sahu, S. S. (1996). Acquired haemophilia and its management (letter). Br. J. Haematol, 92, 773.
   PubMed Web of Science ®Google Scholar
• Huth-Kühne, A., Uhle, C. and Zimmermann, K. (1998). Reinduction of immunetolerance with a combination treatment of IgG-immunoadsorption and high-dose continuous factor VIII replacement in acquired haemophilia (abstract). Haemophilia, 4, 250.
   Google Scholar
• Green, D. (1998). Oral immunosuppressive therapy for acquired haemophilia (letter). Ann. Intern. Med., 128, 325.
   PubMed Web of Science ®Google Scholar
• Liam, E. C.-Y., Larcada, A. F. and Chiu, A. Y.-Z. (1989). Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann. Intern. Med., 110, 774–778.
   PubMed Web of Science ®Google Scholar
• Pfliegler, G., Boda, Z., Hársfalvi, J. et al. (1989). Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII: C inhibitor. Postgrad. Med. J., 65, 400–402.
   PubMed Web of Science ®Google Scholar
• Siegbahn, A., Feltelius, N., Norlén, B. J. and Hedner, U. (1995). Treatment of acquired haemophilia due to factor VIII: C inhibitor with recombinant FVIIa and cyclosporine (abstract). Thromb. Haemost., 73, 1424.
   Web of Science ®Google Scholar
• Schwerdtfeger, R., Hintz, G. and Huhn, D. (1991). Successful treatment of a patient with postpartum factor VIII inhibitor with recombinant human interferon α 2a. Am. J. Haematol, 37, 190–193.
   PubMed Web of Science ®Google Scholar
• Green, D. and Kwaan, H. C. (1987). An acquired factor VIII inhibitor responsive to high-dose gammaglobulin. Thromb. Haemost., 58, 1005–1007.
   PubMed Web of Science ®Google Scholar
• Carreras, L. O., Perez, G. N., Xavier, D. L., Blanco, A. N. and Penalva, L. B. (1988). Autoimmune factor VIII inhibitor responsive to gammaglobulin without in vitro neutralisation (letter). Thromb. Haemost., 60, 343.
   PubMed Web of Science ®Google Scholar
• Heyman, M. P., Chakravathy, A., Edelman, B. B., Needleman, S. W. and Schiffer, C. A. (1988). Failure of high dose iv gammaglobulin in the treatment of spontaneously acquired factor VIII inhibitors. Am. J. Haematol, 28, 191–194.
   PubMed Web of Science ®Google Scholar
• Campion, E. W. (1992). Desperate disease and plasmapheresis (editorial). New Engl. J. Med., 326, 1425–1427.
   PubMed Web of Science ®Google Scholar
• Erskine, J. G., Burnett, A. K., Walker, I. D. and Davidson, J. F. (1981). Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC. BMJ, 283, 760.
   PubMedGoogle Scholar
• Slocombe, G. W., Newland, A. C., Colvin, M. P. and Colvin, B. T. (1981). The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br. J. Haematol., 47, 577–585.
   PubMed Web of Science ®Google Scholar
• Nilsson, I. M. and Freiburghaus, C. (1995). Apheresis. Advances in Experimental Medicine and Biology, 286, 175–184.
   Google Scholar
• Hay, C. R. M., Colvin, B. T., Ludlam, C. A., Hill, F. G. H. and Preston, F. E. (1996). Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul. Fibrinolysis., 7, 134–138.
   PubMed Web of Science ®Google Scholar